Production (Stage)
Cytosorbents Corporation
CTSO
$0.845
-$0.004-0.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 75.72% | -19.92% | 74.61% | 32.67% | 16.89% |
| Total Depreciation and Amortization | -8.69% | -46.08% | -7.31% | -2.38% | 41.10% |
| Total Amortization of Deferred Charges | 1,679.44% | -- | -- | 0.00% | 0.00% |
| Total Other Non-Cash Items | -188.50% | 754.40% | -160.23% | 40,839.02% | 356.57% |
| Change in Net Operating Assets | 76.82% | -519.09% | 660.64% | -124.68% | -149.96% |
| Cash from Operations | 28.26% | 63.45% | 52.73% | 30.85% | -55.39% |
| Capital Expenditure | 95.35% | 27.54% | -6.53% | -108.69% | 91.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 44.87% | -36.14% | -27.15% | -46.82% | 52.77% |
| Cash from Investing | 62.83% | 8.61% | -15.79% | -185.46% | 81.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12,742.29% | -98.63% | -- | -100.00% | -92.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,294.84% | -98.63% | -115.27% | 956.23% | -183.56% |
| Foreign Exchange rate Adjustments | 346.55% | -7.40% | 268.83% | -99.43% | -45.79% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 160.58% | -143.20% | 42.13% | 182.25% | -78.37% |